Precision Oncology PMV Pharmaceuticals Reveals Early Data From Cancer Study In Pretreated Patients
Portfolio Pulse from Vandana Singh
PMV Pharmaceuticals Inc announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE trial, showing that PC14586 achieved efficacy in heavily pretreated patients across multiple tumor types and was well tolerated. The overall response rate was 38% at the Recommended Phase 2 Dose of 2000 mg daily. A recommended phase 2 dose of 2000 mg once daily was selected based on overall safety, pharmacokinetics, and efficacy. PMV plans to initiate a registrational Phase 2 trial in early 2024. PMVP shares are down 39.20% at $2.89.
October 12, 2023 | 6:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PMV Pharmaceuticals' Phase 1/2 trial results show efficacy and tolerability, with a Phase 2 trial planned for 2024. However, PMVP shares are down 39.20%.
The positive trial results indicate potential future success for PMV Pharmaceuticals, which could attract investors. However, the current drop in share price suggests market skepticism or other factors negatively affecting investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100